Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.1.5.2ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
HE.2ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.75.2ORF1abNIID WH-1 Seq F519R840ACCTCATGGTCATGTTATGG2045502521F-17862Japan
KL.1.1ORF1abNIID WH-1 Seq F519R840ACCTCATGGTCATGTTATGG2045502521F-17862Japan
B.1.258.7NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-17866.7Germany
B.1.1.441NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-17866.7Germany
B.1.570NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-17866.7Germany
AY.112.1 (Delta)NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-17866.7Germany
DV.1ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-17878.2Japan
B.1.355NWon-NGTTGCGACTACGTGATGAGG20552884928830R-17881.2South Korea
AY.21 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.531NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.1.396NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
AY.17 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.1.355NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
BQ.1.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
BN.1.3.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.36.35NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.610NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
CH.1.1.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
BF.11.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
AY.92 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
GJ.1.2.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
AY.118 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
XBB.1.42.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17914.1US
B.1.626SYoung-STATACATGTCTCTGGGACCA20452176321782F-17916.5Singapore
DN.1.1.2NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
GA.9NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.75.6NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
GC.2NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BQ.1.1.16NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.524NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.5.2.38NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.1.15.3NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.15NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBRNCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
DJ.1.1.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
CH.1.1.21NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.193NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BL.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FP.3NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
DA.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BQ.1.1.14NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.1.16.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
DN.1.1.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
DN.1.1.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.1.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.99NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBF.1.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
B.1.1.409NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used